UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly
In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $46.00 to $52.00.
BofA Merrill Lynch noted, “Ramucirumab is a monoclonal antibody in development for multiple tumor types, with breast, lung and gastric being the furthest along in development (Phase III). Similar to Roche/Genentech's ~$6bn drug Avastin, ramu works by reducing tumors' access to blood supply. Ramu's specific mechanism of action is somewhat different, and based on pre-clinical and clinical data LLY believes that ramu could have some efficacy and/or tolerability advantages over Avastin. We are introducing preliminary sales estimates for ramu, with a launch in 2015 and sales ramping to a modest $500mn 5 years later.”
Eli Lilly & Co. closed on Tuesday at $44.71.
Latest Ratings for LLY
|Dec 2016||Morgan Stanley||Upgrades||Equal-Weight||Overweight|
|Nov 2016||BMO Capital||Downgrades||Outperform||Market Perform|
|Nov 2016||Atlantic Equities||Downgrades||Overweight||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.